EA201690967A1 - Глазное устройство - Google Patents

Глазное устройство

Info

Publication number
EA201690967A1
EA201690967A1 EA201690967A EA201690967A EA201690967A1 EA 201690967 A1 EA201690967 A1 EA 201690967A1 EA 201690967 A EA201690967 A EA 201690967A EA 201690967 A EA201690967 A EA 201690967A EA 201690967 A1 EA201690967 A1 EA 201690967A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polymer matrix
drug delivery
core
intraocular
polymer
Prior art date
Application number
EA201690967A
Other languages
English (en)
Other versions
EA032183B1 (ru
Inventor
Жан-Мари Ракич
Жан-Мишель Фуадар
Original Assignee
Айд Фарма
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айд Фарма filed Critical Айд Фарма
Publication of EA201690967A1 publication Critical patent/EA201690967A1/ru
Publication of EA032183B1 publication Critical patent/EA032183B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001—Designing or manufacturing processes
    • A61F2240/005—Templates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к устройству для внутриглазной доставки лекарственного средства с замедленным высвобождением, содержащему: (a) сердцевину из полимерной матрицы, в которую примешано по меньшей мере одно терапевтическое средство, и (b) полимерное покрытие, полностью окружающее указанный материал полимерной матрицы; причем указанная сердцевина из полимерной матрицы и полимерное покрытие являются нерастворимыми и инертными во внутриглазных жидкостях, и причем указанное устройство для внутриглазной доставки лекарственного средства с замедленным высвобождением имеет форму деформируемого закругленного элемента, и его необходимо вводить в борозду интактного и/или псевдофакического глаза.
EA201690967A 2013-11-14 2014-11-14 Устройство для внутриглазной доставки лекарственного средства, способ его получения и способы его применения EA032183B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13192889 2013-11-14
PCT/EP2014/074644 WO2015071427A1 (en) 2013-11-14 2014-11-14 Eye device

Publications (2)

Publication Number Publication Date
EA201690967A1 true EA201690967A1 (ru) 2016-10-31
EA032183B1 EA032183B1 (ru) 2019-04-30

Family

ID=49584627

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690967A EA032183B1 (ru) 2013-11-14 2014-11-14 Устройство для внутриглазной доставки лекарственного средства, способ его получения и способы его применения

Country Status (17)

Country Link
US (1) US9999595B2 (ru)
EP (2) EP3566693B1 (ru)
JP (1) JP6602761B2 (ru)
KR (1) KR20160085870A (ru)
CN (1) CN105792812B (ru)
AU (1) AU2014350095B9 (ru)
BR (1) BR112016010638B1 (ru)
CA (1) CA2929684C (ru)
CL (1) CL2016001160A1 (ru)
EA (1) EA032183B1 (ru)
ES (2) ES2864274T3 (ru)
HK (1) HK1223271A1 (ru)
IL (1) IL245405A0 (ru)
MA (1) MA39111A1 (ru)
MX (1) MX2016006142A (ru)
TN (1) TN2016000162A1 (ru)
WO (1) WO2015071427A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10507101B2 (en) 2014-10-13 2019-12-17 W. L. Gore & Associates, Inc. Valved conduit
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
US11523940B2 (en) 2017-03-17 2022-12-13 W. L. Gore & Associates, Inc. Delivery aids for glaucoma shunts
EP3801462A4 (en) 2018-05-24 2022-03-16 Celanese EVA Performance Polymers LLC IMPLANTABLE DEVICE FOR EXTENDED RELEASE OF A MACROMOLECULAR DRUG COMPOUND
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
JP2021532853A (ja) 2018-07-23 2021-12-02 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト 薬物送達のための眼科用装置
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
MX2021015760A (es) 2019-06-27 2022-04-06 Layerbio Inc Sistemas de administracion de medicamentos de dispositivos oculares.
US11399977B2 (en) 2020-06-04 2022-08-02 SpyGlass Pharma, Inc. Ophthalmic implant system for drug delivery
WO2023091333A1 (en) * 2021-11-17 2023-05-25 Celanese Eva Performance Polymers Llc Implantable device for treating an inflammatory eye condition
CN114224822B (zh) * 2022-01-28 2023-07-14 复旦大学附属眼耳鼻喉科医院 一种眼部缓释给药植入物及其制造方法
EP4233836A1 (en) 2022-02-24 2023-08-30 Eyed Pharma Intraocular drug delivery device comprising an eyelet
WO2024020505A2 (en) * 2022-07-22 2024-01-25 SpyGlass Pharma, Inc. Intraocular drug delivery systems and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3618604A (en) 1969-06-09 1971-11-09 Alza Corp Ocular insert
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4718905A (en) * 1986-08-13 1988-01-12 Freeman Jerre M Haptic element using ion beam implantation for an intraocular lens
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5928282A (en) * 1997-06-13 1999-07-27 Bausch & Lomb Surgical, Inc. Intraocular lens
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
FR2787991B1 (fr) * 1998-12-31 2001-05-25 Medicale De Prec S M P Sa Soc Dispositif pour traiter la presbytie ou autre affection oculaire
US7090888B2 (en) * 2002-01-18 2006-08-15 Snyder Michael E Sustained release ophthalmological device and method of making and using the same
FR2844703B1 (fr) 2002-09-25 2005-07-08 Alain Nicolas Gilg Dispositif intraoculaire pour restaurer l'accommodation de l'oeil atteint de presbytie
US20090018650A1 (en) * 2003-06-19 2009-01-15 Boxer Wachler Brian S Ophthalmological zonular stretch segment for treating presbyopia
CN101180086A (zh) * 2005-04-08 2008-05-14 苏尔莫迪克斯公司 用于经视网膜下递送的持续释放植入物
JP5591226B2 (ja) * 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
RU2519193C2 (ru) * 2008-09-12 2014-06-10 Критикал Фармасьютикалс Лимитед Усовершенствование всасывания терапевтических средств через слизистые оболочки или кожу
WO2010101758A1 (en) 2009-03-03 2010-09-10 Alcon Research, Ltd. Peri-corneal drug delivery device
US20130017243A1 (en) * 2010-04-06 2013-01-17 Allergan, Inc. Sustained-release reservoir implants for intracameral drug delivery

Also Published As

Publication number Publication date
HK1223271A1 (zh) 2017-07-28
BR112016010638B1 (pt) 2023-01-31
US9999595B2 (en) 2018-06-19
MX2016006142A (es) 2016-12-09
EP3068372B1 (en) 2019-05-08
CA2929684A1 (en) 2015-05-21
EP3566693A1 (en) 2019-11-13
AU2014350095B9 (en) 2019-09-12
MA39111A1 (fr) 2017-04-28
CN105792812A (zh) 2016-07-20
BR112016010638A2 (ru) 2017-08-08
EA032183B1 (ru) 2019-04-30
CA2929684C (en) 2022-02-22
AU2014350095A1 (en) 2016-06-09
IL245405A0 (en) 2016-06-30
JP2016537370A (ja) 2016-12-01
EP3068372A1 (en) 2016-09-21
JP6602761B2 (ja) 2019-11-06
CN105792812B (zh) 2020-10-23
ES2864274T3 (es) 2021-10-13
TN2016000162A1 (en) 2017-10-06
CL2016001160A1 (es) 2017-03-17
WO2015071427A1 (en) 2015-05-21
ES2740352T3 (es) 2020-02-05
US20160287513A1 (en) 2016-10-06
KR20160085870A (ko) 2016-07-18
EP3566693B1 (en) 2021-02-17
AU2014350095B2 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
EA201690967A1 (ru) Глазное устройство
BR112018003110A2 (pt) nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos
MA49897A (fr) Injecteur sur-corps avec patch adhésif stérile
BR112018010671A8 (pt) dispositivos e métodos de distribuição de fármaco com mudança de forma
CL2016001041A1 (es) Implante intraocular biodegradable que contiene una matriz de polimero biodegradable, polietilenglicol 3350 y una prostamida; uso del mismo en la reducción de la presion ocular en el ojo de un mamifero; aparato para administrar el implante intraocular biodegradable; y método para confeccionar un implante intraocular biodegradable.
NI201500036A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico y métodos para realizarlas y usarlas.
UY35738A (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso
MD20160079A2 (ru) Система доставки лекарственного средства
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
BR102015017380A2 (pt) dispositivo para a reticulação do tecido do olho, e, composição farmacêutica
CR20160477A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y uso
EP3275490A4 (en) Injection needle assembly, and drug injection device
BR112016002646A2 (pt) dispositivos e métodos de entrega de fármaco de múltiplas unidades
EP4173615A3 (en) Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
WO2014179568A3 (en) Two-layer ocular implant
EP3583218A4 (en) TARGETED ACTIVE SUBSTANCE RELEASE ON LIGAND PAYLOAD BASIS FOR CELL THERAPY
AR094289A1 (es) Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
MX2015008286A (es) Composiciones multipolimericas para liberación transdermica de farmaco.
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
DK3432970T3 (da) In vivo lægemiddelleveringsindretninger
IL262062A (en) Implantable ophthalmic drug delivery devices
WO2014113384A3 (en) Lacrimal system drug delivery device
EP3562489A4 (en) DEVICE AND RELATED METHOD FOR INTRAOCULAR MEDICINE ADMINISTRATION
DK3570911T3 (da) Medikamenttilførselsanordning
EP3694497C0 (en) TRANSDERMAL THERAPEUTIC SYSTEM FOR TRANSDERMAL DELIVERY OF GUANFACIN WITH A SILICONE-ACRYLIC HYBRID POLYMER

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM